Alexion Pharmaceuticals, Inc, has announced that the company's co-founder Stephen Squinto, PhD., currently executive vice president and chief global operations officer, will retire effective January 1, 2015. Dr. Squinto co-founded Alexion in 1992 with Leonard Bell, MD, the company’s principal founder and current chairman and chief executive officer.
Dr. Squinto has held numerous leadership positions at Alexion prior to his current role, including executive vice president and head of research and development. While in that role, Dr. Squinto led the development of eculizumab for patients with atypical hemolytic uremic syndrome, resulting in a second approved indication for Soliris (eculizumab) in the United States, Europe, and Japan. He also contributed to Alexion’s acquisition and further development of asfotase alfa as a potential treatment for patients with hypophosphatasia.
Upon Dr. Squinto’s retirement from Alexion on January 1, 2015, he will be the chair of a newly formed Scientific Advisory Board that will provide strategic input into Alexion’s discovery science and pipeline. Dr. Squinto and the Scientific Advisory Board will work directly with Dr. Martin Mackay, executive vice president and global head of research and development.
With Dr. Squinto’s retirement, and as part of Alexion’s succession planning, Alexion has appointed Julie O’Neill to the position of executive vice president, global operations, effective January 1, 2015. She joined Alexion in February 2014 as senior vice president, global manufacturing operations, serving simultaneously as Alexion’s general ganager for Ireland. She has been responsible for leading all aspects of the company’s global supply-chain operations, including the ongoing expansion into Ireland, announced earlier in 2014, and improvements to Alexion’s manufacturing plant in Smithfield, Rhode Island.
Prior to joining Alexion, Ms. O’Neill held leadership positions in pharmaceutical manufacturing and quality for more than 20 years. Most recently, she was vice president of operations and general manager for Ireland at Gilead Sciences, where she established the company’s Irish subsidiary and plant operations and held other cross-functional global leadership roles. Previously, she held leadership positions in operations, manufacturing, and quality functions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She serves as the chairperson for the National Standards Authority of Ireland and is a member of the Governing Body of University College Cork, and is a past president of the Irish Business Employers’ Confederation.
Source: Alexion Pharmaceuticals